The secondary GBM tumors already had TP53 mutation and IDH1 mutation at the time of the low-grade tumors but displayed a 2-fold increase in methylation of the MGMT promoter and an 8% decrease in methylation of LINE-1 during malignant transformation. The gene discussed is TP53; the disease is glioblastoma.